quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 8, 2026

COO Sells $828K Worth of AMR Stock, According to Recent SEC Filing

View original at nasdaq.com
COO Sells $828K Worth of AMR Stock, According to Recent SEC Filing Key Points Whitehead sold 3,901 shares for a total transaction value of approximately ~$828K on June 3, 2026…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Motley Fool Stock Advisor has a total average return of 941%, outperforming the S&P 500's 206% return.

    60% confidence
  • AMR's operating margin has slipped to -2.0% after peaking at nearly 50% in 2022.

    60% confidence
  • AMR stock trades at a P/S ratio of 1.2x, above AMR's lifetime average P/S of 0.6x, indicating it is trading at a relative premium.

    60% confidence
  • Whitehead's average sell-only trade size over the past four events is approximately 18,451 shares; the smaller June 3 sale is explained by reduced remaining share capacity after prior sales.

    60% confidence
  • Whitehead's prior two open-market sales since January 25, 2025 reflect declining sale sizes as available holdings decrease, with the June 3 sale being the smallest disposition in the last four sell transactions.

    60% confidence
  • Alpha Metallurgical Resources was not identified as one of the 10 best stocks for investors to buy now by the Motley Fool Stock Advisor analyst team.

    60% confidence
  • AMR is likely fairly priced at current levels given the oversupplied metallurgical coal market and current valuation.

    60% confidence
  • AMR stock is essentially flat year-to-date as the metallurgical coal market has cooled following several years of tight supply and high demand, and AMR's profit margins have suffered.

    60% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
COO Sells $828K Worth of AMR Stock, According to Recent SEC Filing — Source | Via News | pt.VIA.NEWS